CB — Biolimus A9-eluting stents showed similar outcomes of major adverse cardiovascular events, MI, death and target vessel revascularization when compared to sirolimus-eluting stents (SES), said Patrick W. Serruys, MD, PhD, of the Erasmus Medical Center in Rotterdam, the Netherlands, when he presented the three-year data of the LEADERS trial said Sept. 23 during the 2010 Transcatheter Cardiovascular Therapeutics (TCT) scientific sessions.
